Home › Research › Brain tissue and pathology
Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1
Chunfang A. Xia, Mani Salarian, Christopher J. Gartshore, Antonella Scaglione, Thomas R. Hayes, Shuanglong Liu, Hsiu‐Ming Tsai, Javier Echavarren et al.. Alzheimer s & Dementia, 2026-07-01
Topic: Brain proteins, microglia and lab models
= 7.1 nM) and remarkable selectivity over other proteinopathies. PET imaging demonstrated robust brain uptake and rapid washout in rodents and NHP. In vivo target engagement was confirmed in an AAV-hTDP43 disease model. F]JNJ-TDP43-1 is a promising PET ligand for early diagnosis and evaluating therapies in TDP-43-related diseases.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Xia, C. A., Salarian, M., Gartshore, C. J., Scaglione, A., Hayes, T. R., Liu, S., et al. (2026). Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1. Alzheimer s & Dementia. https://doi.org/10.1002/alz.71675
Vancouver
Xia CA, Salarian M, Gartshore CJ, Scaglione A, Hayes TR, Liu S, et al. Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1. Alzheimer s & Dementia. 2026. doi:10.1002/alz.71675. PMID: 42471754.
BibTeX
@article{xia2026-42471754,
author = {Xia, Chunfang A. and Salarian, Mani and Gartshore, Christopher J. and Scaglione, Antonella and Hayes, Thomas R. and Liu, Shuanglong and Tsai, Hsiu‐Ming and Echavarren, Javier and others},
title = {{Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1}},
journal = {Alzheimer s \& Dementia},
year = {2026},
doi = {10.1002/alz.71675},
pmid = {42471754},
url = {https://doi.org/10.1002/alz.71675}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- = 7.1 nM) and remarkable selectivity over other proteinopathies.
- PET imaging demonstrated robust brain uptake and rapid washout in rodents and NHP.
- In vivo target engagement was confirmed in an AAV-hTDP43 disease model.
- F]JNJ-TDP43-1 is a promising PET ligand for early diagnosis and evaluating therapies in TDP-43-related diseases.
Why it matters
This tracer was tested in rodents and non-human primates, so it is still early-stage and not yet a proven tool in people. If it works in humans, it could help diagnose TDP-43-related diseases earlier and help evaluate therapies.
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 35 of the 96 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 8.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author A. Katrin Szardenings holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Johnson & Johnson (United States): institution h-index 285 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42471754) |
| Free to read | 2 / 2 | Free to read |
| Points | 35 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 35 of the 96 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Brain tissue and pathology
Also in Brain tissue and pathology
124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.